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Abstract
Introduction: Epidemiological prognoses regarding the global spread of post-menopausal osteoporosis can prove somewhat nebulous.
But it is clear that low-energy fractures and their consequences will become an increasingly serious health problem. Therefore it is crucial
to implement prognostic procedures which could more effectively predict the incidence of osteoporosis and its complications.
Material and methods: The study involved 378 female patients aged 40–86 years for whom clinical risk factors of osteoporotic fracture
were analysed. Densitometry (DPX) was performed at femoral neck. The 10–year risk of fracture was assessed according to the British
model of FRAX calculator.
Results: The study group was divided into two, depending on the history of low-energy fractures. Previous osteoporotic fractures were
confirmed in 128 patients. In this group, the mean bone mineral density (BMD) values (0.717 g/cm2) were lower than in the group without
fracture history (0.735 g/cm2). In 33.3% of patients aged 50–59 years and 17% of women aged 60–79 who required medical treatment for
their clinical status (previous fracture), the FRAX value did not meet the criterion of pharmacotherapy administration. Considering BMD
in the calculation of FRAX produced an even higher underestimation of the fracture risk. Of women aged 40–49, 25% were qualified for
pharmacotherapy of osteoporosis. In that particular age category, BMD did not affect the FRAX value. BMD measurement had a higher
discriminatory value among patients aged 50–79, increasing the number of patients requiring therapy by more than 50%.
Conclusions:
1. The FRAX calculator does not always consider the history of low-energy fractures as a criterion sufficient for therapy implementation.
2. Designing a FRAX calculator specifically for the Polish population would be advisable.
(Pol J Endocrinol 2011; 62 (1): 30–36)
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Streszczenie
Wstęp: Prognozy epidemiologiczne dotyczące rozprzestrzenienia osteoporozy pomenopauzalnej na świecie są niepokojące. W związku
z tym konsekwencje złamań niskoenergetycznych będą stanowiły coraz większy problem zdrowotny społeczeństw. Konieczne staje się
zatem wdrożenie postępowań, które będą skuteczniej przewidywały występowanie osteoporozy pomenopauzalnej i powikłań choroby.
Materiał i metody: Występowanie klinicznych czynników złamania oceniano w grupie 378 pacjentek w wieku 40–86 lat. Dodatkowo
u wszystkich kobiet przeprowadzono badanie densytometryczne bliższego końca kości udowej. W celu obliczenia 10-letniego ryzyka
złamania posłużono się modelem brytyjskim kalkulatora FRAX.
Wyniki: W niniejszej pracy grupę badaną podzielono na dwie części w zależności od wywiadu dotyczącego wystąpienia niskoenerge-
tycznego złamania. U 128 pacjentek stwierdzono w przeszłości złamanie osteoporotyczne. W tej grupie średnie wartości gęstości mineral-
nej kości (BMD, bone mineral density) (0,717 g/cm2 ) były niższe niż w grupie bez złamań (0,735 g/cm2 ).
W grupie między 50.–59. rokiem życia, która ze względu na stan kliniczny (wcześniejsze złamanie) wymagała leczenia, wartość FRAX
w 33,3%, a między 60.–79. rokiem życia w 17%, nie spełniała kryterium włączenia farmakoterapii. Uwzględniając FRAX BMD w grupie
między 60.–79. rokiem życia, stwierdzono jeszcze większe niedoszacowanie ryzyka złamań, sięgające 25%.
Wśród kobiet między 40.–49. rokiem życia, bez złamań, 25% kwalifikowała się do farmakoterapii osteoporozy pomenopauzalnej. W tej kategorii
wiekowej dodanie informacji BMD nie wpływało na wysokość FRAX-10. Badanie BMD miało większą wartość dyskryminacyjną wśród chorych
między 50.–79. rokiem życia, zwiększając liczbę włączonych według wskazań do terapii farmakologicznej nawet o ponad 50%.
Wnioski:
1. Kalkulator FRAX nie zawsze uwzględnia wcześniejsze złamanie niskoenergetyczne jako wystarczające kryterium do wdrożenia terapii.
2. Wskazane jest opracowanie kalkulatora FRAX dla polskiej populacji.
(Endokrynol Pol 2011; 62 (1): 30–36)
Słowa kluczowe: terapia osteoporozy, kalkulator FRAX, progi interwencyjne
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Introduction
Osteoporosis is a medical condition characterised by
bone strength reduction and, in consequence, by an in-
creased fracture risk, most often affecting women of
post-menopausal age. In men, osteoporosis (OP) is di-
agnosed mainly in the elderly or may be associated with
the prevalence of other diseases disturbing bone tissue
metabolism. The available epidemiological data is rath-
er confusing. The life risk for any osteoporotic fracture
in women after 50 amounts to 40% [1]. The life risk of
femoral neck fracture in women is higher than the total
risk for breast, endometrial and ovarian neoplasms [2].
In Europe during the year 2000, 3.79 million low-ener-
gy fractures were recorded [3].
Epidemiological data concerning the Polish popu-
lation may be affected by possible defects in the precise
reporting of patient diagnoses to the National Health
Fund. The available data shows 17,625 hip fractures in
Poland [4]. The rapid progress in medical care has con-
tributed to a significant extension of the average life-
span in developed countries. On the other hand,
progress often has unfavourable effects on our lifestyle,
including poor dietary habits (with calcium and vita-
min D3 deficiencies), low physical activity and the wide-
spread use of various stimulants. Such trends will con-
tribute to a growing incidence of osteoporosis, unless
a more effective screening apparatus is implemented to
precisely identify the subjects at risk who will then im-
mediately receive appropriate prophylactic-therapeu-
tic treatment.
In past diagnosis of the disease, BMD was the main
parameter of evaluation. The densitometric criteria, as
arbitrarily defined by the WHO, identified osteoporo-
sis at a T-score £ 2.5 SD, obtained in DPX examination
of the femoral neck and/or of the L1-L4 lumbar spine
[5]. Recent epidemiological studies have proven, how-
ever, that many episodes of low-energy fractures are
recorded in patients who, by the above-mentioned
WHO criteria, did not qualify for a diagnosis of os-
teoporosis, which, in consequence, deprived them of
appropriate pharmacological therapy. It has now been
confirmed that low BMD is an important, but not the
only, fracture-predisposing factor [6].
Twelve studies, involving a group of approximately
60,000 women, have provided evidence for the effects
of other factors on fracture risk [7]. Therefore, osteoporo-
sis diagnosis cannot be derived from BMD measure-
ments alone, but should also take into account history
data. The already known clinical risk factors of os-
teoporotic fractures, treated as reference for the histo-
ry, obtained from patients, allow the identification of
a group of patients predisposed to the disease.
While performing a subjective study, data should
be collected concerning the history of falls during the
last 12 months, concomitant diseases and medications,
which may predispose to an elevated incidence of frac-
tures. See Table I for the clinical risk factors of os-
teoporotic fractures.
The risk of low-energy fractures, including those of
the femoral neck, increases with age. A low-energy frac-
ture episode may be prognosed in 30–50% of women
and 15–30% of men. [8–10]. These numbers transpose
into increased mortality rates, especially in patients over
70. Within 12 months of suffering a fracture, 20–45% of
patients die of fracture-related complications, while
impaired physical ability and considerably diminished
life quality are even more frequently observed [11–13].
The decision to start therapy of osteoporosis is made by
a doctor on the basis of calculated, individual, 10-year
risk assessment for low-energy fracture.
In 2008, a team from Sheffield in the UK designed
the FRAX calculator, a diagnostic screening tool for frac-
ture risk calculation. It is an easy means of quick risk eval-
uation and supports individual therapeutic decisions [14,
15]. The therapeutic threshold is defined with regards to
the current epidemiological situation and the financial
position of the given state. Other available osteoporotic
fracture risk calculators can also be used in therapeutic
decision making, including OSC Recommendations for
Bone Mineral Density Reporting or QFracture Scores [16].
The goal of performed diagnostics in a patient with os-
teoporosis is to determine an individual 10-year fracture
risk, followed by a therapeutic programme, based on
accepted therapeutic thresholds.
Because of the difficulties of defining the levels for
these thresholds in the Polish population, we accepted
age-related therapeutic thresholds, following the algo-
rithm of Kanis et al. [14].
Our study aimed at evaluating the FRAX calculator,
regarding its usefulness in qualifying Polish female pa-
tients for osteoporosis treatment.
Table I. Clinical risk factors of low-energy fractures
Tabela I. Kliniczne czynniki ryzyka złamań osteoporotycznych
Clinical risk factors
Low-energy fracture in past
Femoral fracture in parents
Current tobacco smoking
Intake of glucocorticosteroids
Rheumatoid arthritis
BMI (body mass index) < 19
Excess alcohol intake
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Material and methods
The study group involved 378 female patients of the
Endocrinological Outpatient Clinic at the Clinical Hos-
pital in Poznan. Their ages ranged from 40 to 86 years
(mean age: 67.4). In all patients, densitometry (by Lu-
nar DPX-L, in which error repeatibility equals max.
1.5%) at the femoral neck was performed. Additional-
ly, following a medical history, including clinical risk
factors of osteoporotic fractures, calculation of 10-year
risk of fracture was carried out, using the calculator
which is available at http://www.sheffield.ac.uk/FRAX
(in the version designed for the British population).
The calculations were performed twice. The first
series considered the clinical risk factors only (FRAX).
The second, verifying, series of calculations additional-
ly accounted for BMD obtained from densitometric ex-
amination (FRAX BMD). In the analysis, the major FRAX
was used, evaluating the risk level of main osteoporot-
ic fractures (vertebral, antebrachial, femoral and humer-
al). The study group was divided into five age catego-
ries, with 10-year intervals, starting from the age of 40.
The thresholds for therapeutic intervention were de-
termined from literature data, as per the study by Ka-
nis et al. [7]. Our research was performed between 2006
and 2009.
Results
The prevalence of recognised clinical risk factors for
osteoporotic fractures was evaluated in the studied
group of patients. Previous low-energy fractures were
recorded in 128 (33.8%) women. An additional family
history of hip fracture was obtained in 97 patients
(25.7%). See Table II for the prevalence of particular clin-
ical fracture risk factors in the studied group.
Results of densitometry
In the studied group, BMD values from 0.537 g/cm2 to
0.998 g/cm2 (mean value: 0.741 g/cm2) were obtained. In
the patients with a history of low-energy fracture, BMD
varied from 0.537 g/cm2 to 0.960 g/cm2 (mean value: 0.717
g/cm2 ± 0.1 SD).
BMD in the women without osteoporotic fracture
in their history varied from 0.552 g/cm2 to 0.998 g/cm2
(mean value: 0.735 g/cm2 ± 0.12 SD).
Fracture risk evaluation
The analyses were performed separately in groups of
patients with and without a history of osteoporotic frac-
ture. Having completed FRAX and FRAX BMD calcula-
tions, it was found that the 10-year fracture risk for the
patients without a fracture history varied from 6.5% to
54% without BMD consideration, and from 4.5% to 60%
for FRAX BMD. See Tables III and IV for the mean val-
ues of BMD, T-score and FRAX, with and without BMD
in particular age categories.
Comparisons of BMD, FRAX and FRAX BMD val-
ues between groups with and without fractures in their
medical history are presented in Figures 1, 2, and 3.
Analysis of therapeutic intervention thresholds
Based on the approved therapeutic decision thresholds,
we evaluated how many patients in particular age
groups qualified for pharmacotherapy administration.
See Tables IV and V for the number of patients with
a 10-year probability of fracture exceeding the accept-
ed therapeutic thresholds.
Additionally, for the patients without low-energy frac-
tures in their past history, FRAX and FRAX BMD values
were compared, depending on the applied calculator, for
the French or the British population, being then referred
to the therapeutic thresholds accepted in the reported
study (Table VI). We assessed the percentage of women
who should have been submitted to anti-osteoporotic ther-
apy, based on the accepted calculator model.
Results from an earlier study at Department of Fam-
ily Medicine at Medical University in Poznan, were
used, introducing the FRAX algorithm, normalised for
the Polish population [17].
The highest differences were noted in women aged
60–69, in whom the fracture risk, calculated without BMD
consideration, acc. to the French and the British calculators,
was 0% and 11.7%, respectively. The FRAX BMD value, acc.
to the French model, was 3.3% as against 19.5% obtained
from the British calculator (the therapy--demanding group
larger by 16.2%). See Table VII for obtained results.
Discussion
Identifying a group of patients who will certainly
achieve individual therapy-related health improve-
ment, is a key problem in the decision about pharma-
Table II. Distribution of low-energy fracture risk factors in
the group of 378 women
Tabela II. Rozkład czynników ryzyka złamania niskoenerge-
tycznego w grupie 378 chorych
Risk factor n %
Low-energy fracture in patient’s history 128 33.8
Parental history of hip fracture 97 25.7
Current tobacco smoking 48 12.7
BMI < 19 5 1.3
Rheumatoid arthritis 0 0
Glucocorticosteroid therapy 0 0
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cological therapy of osteoporosis, because incurred ex-
penses will then gain social acceptance. It is assumed that
an evaluation of the absolute fracture risk in 10-year per-
spective is, for the time being, an optimal solution.
The cost-effectiveness of osteoporosis therapy has
been confirmed for the British population with 10-year
fracture risk over 7.5% in 50 year-old women. In subse-
quent age intervals, the threshold determined for phar-
macotherapy onset is gradually getting higher, reach-
ing 30% in the oldest age group.
The acceptance of particular therapeutic thresholds
was proposed, following studies of osteoporosis thera-
Table III. BMD, FRAX and FRAX BMD values in patients without fracture history (n = 250)
Tabela III. Wartości BMD, FRAX, FRAX BMD u pacjentek bez złamań (n = 250)
Age category n BMD  ± SD T-score  ± SD FRAX major (%) FRAX major BMD (%)
40–49 11 0.87 ± 0.1 –0.88 ± 0.77 3 (2.4–3.5) 3.4 (2.5–5.4)
50–59 54 0.82 ± 0.13 –0.72 ± 1.1 5.7 (3.5–14) 7.2 (3.3–19)
60–69 77 0.77 ± 0.11  –1.7 ± 0.9 9.2 (4–20) 11 (3.1–25)
70–79 89 0.72 ± 0.1 –2.2 ± 0.8 15.5 (9.2–35) 17.2 (7.9–49)
> 80 19 0.73 ± 0.1 –1.9 ± 1.4 18.7 (13–32) 16.6 (8.1–38)
Table IV. BMD, FRAX and FRAX BMD in patients with fracture history (n = 128)
Tabela IV. Wartości BMD, FRAX, FRAX BMD u pacjentek ze złamaniami (n = 128)
Age category n BMD  ± SD T-score  ± SD FRAX major (%) FRAX major BMD (%)
40–49 3 0.94 ± 0.2 –0.9 ± 1.9 8.4 (6.4–15) 8.8 (4.5–11)
50–59 12 0.77 ± 0.1 –1.4 ± 1.6 13.1 (8.7–23) 15.3 (7.7–30)
60–69 34 0.74 ± 0.09 –2.1 ± 0.8 20 (11–33) 21.5 (9.4–38)
70–79 68 0.69 ± 0.09 –2.3 ± 0.8 26.1 (7–46) 27.7 (13–69)
> 80 11 0.68 ± 0.04 –2.5 ± 0.3 34.7 (24–54) 28.9 (21–44)
Figure 1. Comparison of BMD values in group with and without
fractures according to age category
Rycina 1. Porównanie wartości BMD w grupie z i bez złamań w
zależności od kategorii wiekowej
Figure 2. Comparison of FRAX BMD values in group with and
without fractures according to age category
Figure 2. Porównanie wartości FRAX BMD w grupie z i bez
złamań w zależności od kategorii wiekowej
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py cost-effectiveness, taking into account the funds for
osteoporosis treatment vs. the state budget outlays for
the treatment of osteoporotic fractures [18]. In those cal-
culations, indirect costs were also accounted for, i.e.
those costs associated with periods of absence from
work, long-term rehabilitation or the necessity to be
covered by disability pension programmes or to receive
sickness benefits [19, 20].
In the UK, the prevalence of hip fracture is 372/
/100,000 subjects vs. the average number of 224/100,000
subjects for the Polish population [21, 22]. A particular
model of the FRAX calculator, designed for the popula-
tion of a given country, is based on the epidemiological
data, concerning the incidence of proximal femur and
extravertebral fractures. However, no Polish version has
thus far been created, one of the obstacles being divergent
epidemiological data concerning the hip fracture inci-
dence in Poland. Depending on a given region of the
country, the researcher and the accepted method of cal-
culations, the figures vary from 165/100,000 to 283/100,000
[10, 19, 20]. At present, the British model of the calculator
is recommended to be used for Polish patients.
Low-energy fracture is a recognised risk factor for
the occurrence of subsequent fractures. The FRAX cal-
culator is not an ideal tool, partly because one of the
FRAX-determining factors is the information on previ-
ous osteoporotic fracture(s); although, as a rule, all those
patients should already have been treated, thus ques-
tioning the sense of FRAX calculation at the time of the
reported study.
Table V. Patients without fractures (n = 250) who met the FRAX- and FRAX BMD-related criteria for starting therapy
Tabela V. Liczba pacjentek bez złamań (n = 250) spełniających warunki włączenia terapii przeciwosteoporotycznej na podstawie
FRAX i FRAX BMD
Age category Therapeutic Patients in a given Patients above Patients above FRAX BMD-
threshold (%)  age group  FRAX-related threshold  -related threshold
40–49 5 11 3 (27.3%) 3 (27.3%)
50–59 10 54 5 (9.3%) 10 (18.6%)
60–69 15 77 9 (11.7%) 15 (19.5%)
70–79 20 89 17 (19.1%) 25 (28%)
> 80 30 19 1 (5.3%) 1 (5.3%)
Table VI. Patients with fractures (n=128), who met the FRAX- and FRAX BMD-related criteria for starting therapy
Tabela VI. Liczba pacjentek ze złamaniami (n= 128) spełniających warunki włączenia terapii przeciwosteoporotycznej na
podstawie FRAX i FRAX BMD
Age category Therapeutic Patients in a given Patients above FRAX- Patients above FRAX BMD-
threshold (%)  age group -related threshold -related threshold
40–49 5 3 3 (100%) 2 (66.7%)
50–59 10 12 8 (66.7%) 8(66.7%)
60–69 15 34 28 (82.4%) 26 (76%)
70–79 20 68 56 (83.6%) 50 (74.6%)
> 80 30 11 5 (45.4%) 4 (36.4%)
Figure 3. Comparison of FRAX values in group with and without
fractures according to age category
Figure 3. Porównanie wartości FRAX w grupie z i bez złamań
w zależności od kategorii wiekowej
35
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
The study group was divided according to fracture
history. The highest incidence of osteoporotic fractures
in the studied group (46.6%) was noted in the age group
of 70–79, while the lowest (18.2%) was observed in the
group with subjects between the 50th and the 59th years
of life. Loss of height over 4cm was not, however, con-
sidered in those analyses. While it is true that, usually,
this is evidence of other, clinically silent fractures of
vertebral bodies, it is striking how height loss often pass-
es totally unnoticed, either by the patients themselves
or their physicians. At the root of this peculiar lack of
perception is the relatively high number of undiagnosed
compressive vertebral fractures. Since loss of height was
in the reported study only communicated by the pa-
tients, the parameter was not taken into account, fear-
ing the lack of precise data in the calculations.
In order to check the FRAX calculator sensitivity,
fracture risk levels were also calculated for the patients
in whom therapy had already been continued due to
low-energy fracture in the past. Interestingly, having
completed the calculations for those patients, the
10-year fracture risk was either not the same in all of them
or exceeded the already established therapeutic thresh-
olds. In the group aged 50–59, having completed FRAX
and FRAX BMD calculations, as many as one in three of
the women did not meet the pharmacotherapy start-
ing criterion. It is important to note that the women
were usually very active at the time of the reported
study, thus any experienced fracture could have signif-
icantly decreased their quality of life, while on the oth-
er hand, if FRAX calculations had rigidly been followed,
those women would have been deprived of any thera-
py. In the group of patients between the 60th and the
79th year of life, the FRAX index eliminated 17% of those
patients from therapy. Having taken into account addi-
tional BMD measurements, even higher underestimation
was confirmed. Following FRAX BMD results, the thera-
py starting criterion was not met in approximately one
quarter of the patients, despite its clinical necessity.
Even higher divergencies were observed in women
aged > 80, but the rather small number of patients in
that age group makes it unsafe to draw conclusions.
Regarding patients aged 40–49 with no history of
fractures, the results of FRAX calculations qualified only
25% of those patients for therapy. Neither did FRAX
BMD change in any way the obtained values of the
10-year risk of fracture. Hip BMD measurements were
more significant in the patients between the 50th and
the 79th year of life, substantially increasing the number
of patients to be treated (in the age group of 50-59 years,
the number of those patients grew by 100% and, in the
group aged60–70 by 50%). In patients over 80 years, for
whom the therapeutic threshold was set at > 30%,
densitometry examination had no effect on the thera-
peutic decision. It seems then that, with older patients,
DPX influences fracture risk evaluation less than with
younger patients and that the obtained results are in
line with earlier observations [18].
Due to the different, population-related incidence
of hip fractures in the UK population vs. the Polish pop-
ulation, FRAX calculations, performed in earlier stud-
ies of the team of authors, were based on the French
pattern. This selection was dictated by the incidence of
fractures in France, the closest to the Polish data pub-
lished at that time [19]. Comparing the percentages of
therapy-qualifying patients in the results of the French
and the British calculator, considerable differences were
demonstrated for each age catergory. Using the FRAX
calculator for the French population, the number of
patients qualified for treatment was distinctly lower. The
biggest differences concerned women aged 50–69, in
whom the fracture risk was evaluated on the basis of
clinical data, as well as BMD values. In turn, FRAX, cal-
culated according to the French model for patients aged
60–69 and with no history of fractures, was 0% vs. 11.7%
for the British model. Having added the results of prox-
imal femoral bone densitometry, the divergence of re-
sults was even higher, amounting to 3.3% vs. 19.5%,
respectively.
By contrast, in the group of patients aged > 80, cal-
culations in the British version demonstrated lower
percentage values of the patients qualifying for thera-
py vs. those in the French version (5.3% vs. 23%); but,
as has already been mentioned, the small number of
patients in the group does not allow the drawing of any
conclusions.
Taking into account the differences in the published
data concerning the incidence of fractures in Poland,
any application of a calculator designed for another
Table VII. Percentage of patients qualifying for therapy by
obtained results, regarding earlier analyses for the Polish
population, following the French and the British FRAX model
Tabela VII. Porównanie odsetka pacjentów kwalifikujących
się do leczenia na podstawie uzyskanych wyników z
wcześniejszymi analizami dla populacji polskiej według
modelu francuskiego i brytyjskiego
FRAX FRAX BMD
France UK France UK
50–59 0% 9.3% 6.3% 18.6%
60–69 0% 11.7% 3.3% 19.5%
70–79 9% 19.1% 17% 28%
> 80 23% 5.3% 23% 5.3%
FRAX — calculations based on clinical risk factors; FRAX BMD —
calculations with an additional consideration of DPX
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population bears a risk of error. This suggests the need
to precisely determine the number of hip fractures for
the entire population of Poland, and then use the re-
sults to design a calculation tool specifically for the Pol-
ish data. Otherwise, any intervention, based on frac-
ture risk calculation with a FRAX calculator in a version
designed for other populations, could be biased and, in
consequence, affect patients with compromised results
of applied therapy.
Conclusions
1. FRAX calculator does not always account for previous
low-energy fracture as a therapy starting criterion.
2. The use of the British FRAX model increased the
number of patients qualifying for osteoporosis phar-
macotherapy compared to the French FRAX model.
3. It is necessary to design a Polish version of the FRAX
calculator.
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